-
UPDATE: BMO Capital Starts Vertex (VRTX) at Market Perform
-
Vertex (VRTX) PT Raised to $248 at BMO Capital
-
Vertex (VRTX) PT Raised to $240 at BMO Capital
-
Vertex (VRTX) PT Trimmed to $232 at BMO Capital
-
Vertex (VRTX) PT Raised to $235 at BMO Capital
-
Vertex (VRTX) PT Raised to $234 at BMO Capital
-
Vertex (VRTX) PT Lowered to $192 at BMO Capital
-
Vertex (VRTX) PT Raised to $204 at BMO Capital; 'Stellar Revenue'
-
Vertex Pharma (VRTX): Orkambi Beat Offset By Spending - BMO
-
Vertex Pharma (VRTX): Raising PT Nearly 50% - BMO
-
World stocks tally ninth day of gains as earnings pick up
-
BMO Capital Upgrades Vertex (VRTX) to Outperform Following Tezacraftor Validation In Phase III
-
BMO Capital Maintains Market Perform Rating and $78 PT on Vertex Pharma (VRTX) Following Concert CTP-656 Acquisition
-
Vertex Pharma (VRTX): Nivalis Setback Positive For Orkambi - BMO
-
Vertex (VRTX) PT Bumped to $88 at BMO Capital Following Results and Triple Combo Update
-
Vertex (VRTX), BioMarin (BMRN), Intercept (ICPT), Others Highlighted as Targets at BMO Following PFE/MDVN
-
BMO Capital Starts Vertex (VRTX) at Market Perform
-
Notable Analyst Rating Changes 2/1: (JOY) (PFPT) (VRTX) Upgraded; (ARR) (GPC) (AIG) Downgraded
-
Notable Analyst Rating Changes 9/14: (NOK) (VRTX) (EXC) Upgraded; (MRVL) (GFI) (ALXN) Downgraded
-
Notable Analyst Rating Changes 4/10: (NFLX) (M) (KNX) Upgraded; (CAB) (HBHC) (AAPL) Downgraded
-
Notable Analyst Rating Changes 10/13: (NAVI) (VRTX) (SFUN) Upgraded; (JCP) (ONNN) (PBF) Downgraded
-
Notable Analyst Rating Changes 11/28: (AKAM) (AKS) (OMC) Upgraded; (CTL) (ESV) (VRTX) Downgraded
-
Notable Analyst Rating Changes 08/17: (ECA) (ODP) (VRTX) Upgraded; (FSLR) (HPQ) (IMAX) Downgraded
-
Notable Analyst Rating Changes 03/08: (NVDA) (EXPE) (MDC) Upgraded; (VRTX) (HK) (QCOM) Downgraded
-
BMO Capital Downgrades Vertex (VRTX) to Market Perform